D. E. Shaw & Co., Inc. Vaxart, Inc. Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Vaxart, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 174,606 shares of VXRT stock, worth $116,986. This represents 0.0% of its overall portfolio holdings.

Number of Shares

174,606

Previous 107,768 62.02%

Holding current value

$116,986

Previous $61,000 270.49%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.56 - $1.41 $37,429 - $94,241	66,838 Added 62.02%	174,606 $226,000
Q4 2023 Feb 14, 2024	BUY	$0.57 - $0.85 $55,275 - $82,428	96,975 Added 898.5%	107,768 $61,000
Q3 2023 Nov 14, 2023	SELL	$0.69 - $0.85 $171,618 - $211,414	-248,723 Reduced 95.84%	10,793 $8,000
Q2 2023 Aug 14, 2023	SELL	$0.6 - $1.41 $433,120 - $1.02 Million	-721,867 Reduced 73.56%	259,516 $189,000
Q1 2023 May 15, 2023	SELL	$0.71 - $1.25 $174,109 - $306,530	-245,224 Reduced 19.99%	981,383 $745,000

Q4 2022 Feb 14, 2023	BUY	$0.75 - $2.24 $492,487 - $1.47 Million	656,650 Added 115.21%	1,226,607 $1.18 Million
Q3 2022 Nov 14, 2022	SELL	$2.09 - $4.5 $983,196 - $2.12 Million	-470,429 Reduced 45.22%	569,957 $1.24 Million
Q2 2022 Aug 15, 2022	SELL	$2.7 - $5.28 $1.49 Million - $2.92 Million	-552,255 Reduced 34.68%	1,040,386 $3.64 Million
Q1 2022 May 16, 2022	SELL	$4.29 - $6.64 $2.29 Million - $3.55 Million	-534,283 Reduced 25.12%	1,592,641 $8.03 Million
Q4 2021 Feb 14, 2022	BUY	$5.77 - $7.96 $5.73 Million - $7.91 Million	993,652 Added 87.68%	2,126,924 $13.3 Million
Q3 2021 Nov 15, 2021	BUY	$6.67 - $9.8 $7.47 Million - $11 Million	1,119,856 Added 8347.17%	1,133,272 $9.01 Million
Q2 2021 Aug 16, 2021	BUY	$5.06 - $10.78 $67,884 - $144,624	13,416 New	13,416 $100,000

Others Institutions Holding VXRT

# of Institutions

106

Shares Held

25M

Call Options Held

77K

Put Options Held

45.8K

View Full List

About Vaxart, Inc.

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $84.8M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

More about VXRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account